Intra-Cellular Therapies (ITCI) PT Cut to $22 at Piper Jaffray; Thinks Trial Not Drug a Failure

September 29, 2016 6:47 AM EDT
Get Alerts ITCI Hot Sheet
Price: $14.19 -4.96%

Rating Summary:
    7 Buy, 2 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 11
Trade ITCI Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Piper Jaffray analyst Charles Duncan slashed his price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $22.00 (from $57.00) after the company announced that its second P3 in schizophrenia failed to meet the primary endpoint, with ‘007 generating improvements in the PANSS that were over-shadowed by a higher-than-expected placebo response. The analyst maintained an Overweight rating.

The analyst thinks the trial was a failure not the drug.

Duncan commented, "We expect sentiment for this name to be challenged for the next ~6mos, pending further data and the outcome of an FDA meeting, and are cutting our PT to $22. However despite execution-related issues with 302, we believe '007 is still a viable, differentiated drug candidate for treating psychosis and other symptoms. We continue to see a regulatory path forward in schizophrenia, with options including another trial or submission on the current data - with/without bipolar. Overall, while there is heightened risk and reduced visibility in the near-term for ITI-007, we see the current down draft (the stock traded at ~$14 after hours) as a buying opportunity for patient investors. We reiterate OW in advance of regulatory/data updates which may come as soon as early ‘17."

For an analyst ratings summary and ratings history on Intra-Cellular Therapies click here. For more ratings news on Intra-Cellular Therapies click here.

Shares of Intra-Cellular Therapies closed at $42.35 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA

Related Entities

Piper Jaffray, The Children's Investment Fund (TCI), Charles Duncan

Add Your Comment